Stock ATXI AVENUE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-06-17 EDT 		5-day change 1st Jan Change
3.56 USD -4.04% Intraday chart for Avenue Therapeutics, Inc. +5.01% -70.52%
05-16 Avenue Therapeutics, Inc Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) CI
05-15 Avenue Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Capitalization 1 159.9 99.64 5.544 2.133 3.35 - -
Enterprise Value (EV) 1 159.9 99.64 5.544 2.133 3.35 3.35 3.35
P/E ratio -5.82 x -19.2 x -0.71 x -0.16 x -0.62 x -1.07 x -1.25 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA - - - - - - -
EV / FCF - - - -143,821 x - - -
FCF Yield - - - -0% - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 14.8 14.9 63.7 177 941 - -
Reference price 2 10,800 6,694 87.00 12.08 3.560 3.560 3.560
Announcement Date 20-03-30 21-03-31 23-03-30 24-03-18 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net sales 1 - - - - - - -
EBITDA - - - - - - -
EBIT 1 -26.26 -5.213 -8.043 -14.54 -14.01 -15.2 -17.36
Operating Margin - - - - - - -
Earnings before Tax (EBT) 1 -25.91 -5.151 - -10.49 -14.01 -15.2 -17.36
Net income 1 -25.91 -5.151 -3.552 -10.38 -14.01 -15.2 -17.36
Net margin - - - - - - -
EPS 2 -1,856 -348.8 -122.3 -73.50 -5.740 -3.330 -2.850
Free Cash Flow - - - -14.83 - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 20-03-30 21-03-31 23-03-30 24-03-18 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - -
EBITDA - - - - - - - - - -
EBIT 1 - -3.912 -6.429 -3.923 -2.068 -2.119 -3.708 -3.2 -3.4 -3.7
Operating Margin - - - - - - - - - -
Earnings before Tax (EBT) 1 - - - - - 0.617 -4.349 -3.2 -3.4 -3.7
Net income 1 -0.662 0.575 -7.536 -4.007 0.526 0.64 -4.34 -3.2 -3.4 -3.7
Net margin - - - - - - - - - -
EPS 2 -33.75 92.25 -102.8 -39.00 4.500 42.00 -15.40 -1.050 -1.110 -1.210
Dividend per Share - - - - - - - - - -
Announcement Date 22-11-10 23-03-30 23-05-10 23-08-10 23-11-13 24-03-18 24-05-15 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - -14.8 - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 20-03-30 21-03-31 23-03-30 24-03-18 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.56 USD
Average target price
12 USD
Spread / Average Target
+237.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AVENUE THERAPEUTICS, INC. Stock Avenue Therapeutics, Inc.
-70.52% 3.35M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.42% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.02% 113B
ARGENX SE Stock argenx SE
+3.14% 22.66B
BIONTECH SE Stock BioNTech SE
-16.20% 21.34B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.57% 16.92B
BEIGENE, LTD. Stock BeiGene, Ltd.
-11.63% 16.68B
GENMAB A/S Stock Genmab A/S
-16.15% 16.61B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.68% 13.62B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.16% 11.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ATXI Stock
  4. Financials Avenue Therapeutics, Inc.